Seyed Alireza Javadinia: Capecitabine-Enhanced Brachytherapy in Locally Advanced Cervical Cancer
Seyed Alireza Javadinia, Clinical Oncologist, Vice President for Research and Technology at Sabzevar University of Medical Sciences, shared a post on LinkedIn:
“Thrilled to share that I’ve published a new article in Cancer Investigation, in collaboration with Dr. Indira Giri, Dr. Soudeh Arastouei, and Prof. Malihe Hasanzadeh mofrad!
Our phase II trial, accessible at tandfonline.com, investigates the safety and efficacy of capecitabine as a radiosensitizer during brachytherapy for locally advanced cervical cancer (FIGO stage IB2-IVA). Key findings show that capecitabine is well-tolerated, with manageable side effects like fatigue (55.6%) and nausea (50%), and no significant increase in chronic adverse events. While it numerically prolonged disease-free survival (DFS) and reduced recurrence risk (HR=0.81), the results were not statistically significant (p=0.75), suggesting further research is needed.
Proud of our collaborative effort to advance cervical cancer treatment options, especially in resource-constrained settings!
Please read, share, and share your feedback.”
Authors: Fatemeh Homaei Shandiz, Soudeh Arastouei, Sare Hosseini, Seyed Alireza Javadinia et al.
More posts featuring Seyed Alireza Javadinia on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023